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Abstract.  Subtractive immunization allowed the isola- 
tion and characterization of monoclonal antibodies that 
specifically inhibit metastasis but not proliferation of 
highly metastatic human tumor cells.  The tolerizing 
agent cyclophosphamide was used to suppress the im- 
mune system in mice to dominant immunodeter- 
minants present on a non-metastatic variant (M-) of 
the human epidermoid carcinoma cell line (HEp3). 
Mice were then inoculated with a highly metastatic 
variant (M  ÷) of HEp3 to enhance an immune response 
to antigenic determinants present on metastatic cells. 
Hybridomas were generated and screened by ELISA 
for differential reactivity to M  ÷ HEp3 over M- HEp3 
cells. This experimental approach, termed subtractive 
immunization (S.I.), was compared to a control immu- 
nization protocol, which eliminated the cyclophospha- 
mide treatment. The S.I. protocol resulted in an eight- 
fold increase in the proportion of mAbs that react with 
molecules enriched on the surface of the M  ÷ HEp3 
cells. Two of the mAbs derived from the S.I. pro- 
tocol, designated DM12-4  and  1A5, were purified and 
examined for their effect in a metastasis model system 
in which chick embryos are transplanted with primary 
HEp3 tumors. Purified mAbs DM12-4  and 1A5, inocu- 
lated i.v. into the embryos, inhibited spontaneous 
metastasis of HEp3 cells by 86 and 90%,  respectively. 
The mAbs are specifically anti-metastatic in that they 
have no effect on the growth of HEp3 cells in vitro 
nor did they inhibit primary tumor growth in vivo. 
The mAbs recognize M  ÷ HEp3 cell surface molecules 
of 55 kD and 29 kD,  respectively.  These data demon- 
strate that the S.I. protocol can be used for the devel- 
opment of unique mAbs that are reactive with anti- 
genic determinants whose expression is elevated on 
metastatic human tumor cells and which function 
mechanistically in the metastatic cascade. 
M 
ETASTATIC dissemination of  malignant tumor cells 
is a complex process which involves a multitude 
of steps,  including  migration  of primary tumor 
cells  through the local underlying stroma and invasion of 
the cells into blood vessels and lymphatics to gain access to 
the host circulation. The tumor cells survive in the vascula- 
ture, arrest, and finally invade and grow at distant secondary 
sites (8, 22, 23, 32). Due to the multiplicity and biochemical 
complexity of  the steps involved in the spread of  tumor cells, 
an understanding  of the metastatic process at a molecular 
level is yet to be fully obtained. 
In order for the tumor cells to complete the malignant pro- 
cess successfully they must express a unique set of  character- 
istics. Many of these traits appear to be associated with mol- 
ecules on the cell surface (16, 29, 33, 39, 42, 47). Changes 
in the level of expression of these surface molecules could 
contribute  to the distinct  phenotypic  differences between 
metastatic and non-metastatic tumor cells (7, 14, 21, 25, 40, 
43). In an effort to identify  and characterize cell surface mol- 
ecules that play a functional role in the metastatic cascade, 
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immunological  approaches  for the generation  of specific 
mAbs have been attempted (2,  11,  15,  17, 45, 51). One ap- 
proach to develop mAbs to cell surface molecules that play 
a functional role in metastasis involves direct immunization 
of mice with intact  metastatic  tumor cells.  However, this 
technique can be inefficient since the tumor cell surface pro- 
vides a large array of antigenic determinants that can be im- 
munodominant and may play no functional role in metasta- 
sis. Reducing the recognition of common, immunodominant 
cell surface molecules would increase the chances of  produc- 
ing antibodies to low abundant but functionally relevant cell 
surface molecules. One way of achieving this goal is through 
the use of the immunosuppressive agent cyclophosphamide 
(19, 24,  38,  44,  49)  coupled  to immunizations  with two 
phenotypically distinct cell variants used as sequential im- 
munogens. Cyclophosphamide selectively kills activated B 
cells  (24,  38)  and can  be  used  to  suppress  the immune 
system in mice to common cell surface antigens present on 
a non-metastatic cell variant used as the initial immunogen. 
After treatment  with  cyclophosphamide,  a phenotypically 
distinct but related metastatic cell variant is inoculated into 
mice to generate mAbs that are reactive to unique molecules 
on the cell surface of  the second cell variant. Cyclophospha- 
mide has been used in suppressive immunization procedures 
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cells (26, 27) and to specific antigens on tumor cells (18, 45, 
48). In addition, the cyclophosphamide immunosuppression 
method has been shown to yield significantly more mAbs to 
specific antigens than a neonatal tolerization method (37). 
In the present study a variation of the subtractive immuni- 
zation (S.I.) ~ approach was used (49). Immunizations were 
performed with human epidermoid carcinoma (HEp3) cells 
from  which a  highly metastatic  variant,  metastatic  HEp3 
Cell  Variant  (M  +  HEp3),  and  a  non-metastatic  variant, 
Non-Metastatic HEp3 Cell Variant (M- HEp3), can be iso- 
lated (12, 31, 34, 35, 46). Cyclophosphamide was employed 
at various  times  after  M-  HEp3  cell  inoculations to  sup- 
press the immune response in mice to common antigenic de- 
terminants present on HEp3 cells.  This suppression proce- 
dure  was  followed  by  multiple  inoculations with  the  M ÷ 
HEp3  variant.  Hybridomas  were  made  from  the  im- 
munoresponsive  mice  and  screened  for  mAbs  that  were 
differentially  reactive  to  M +  HEp3.  This  S.I.  approach 
resulted in the generation of specific mAbs that react with 
molecules that are enriched on the surface of the M + HEp3 
cells as compared to their M- variants.  Some of these mAbs 
are uniquely anti-functional and inhibit metastasis  in an in 
vivo metastasis  model system. 
Materials and Methods 
Cell Lines 
Human breast adenocarcinoma cells (MDA-MB 231), human cervix epider- 
moid carcinoma cells (MS751),  human cervical carcinoma cells (HT-3) and 
human foreskin fibroblasts were obtained from American Type Culture Col- 
lection (Rockville, MD).  Human primary keratinocytes were a gift from 
Dr. Lorne Taichman (SUNY, Stony Brook, NY). HEp3 cells were main- 
tained as monolayer cultures and were obtained from solid HEp3 tumors 
that were serially passaged on the chorioallantoic membranes (CAMs) of 
chick embryos (34-36). The metastatic variant of HEp3 cells, M + HEp3, 
was cultured for 25 d or less before use. The nonmetastatic variant, M- 
HEp3, was maintained in culture for at least 60-80 d before use. Cells were 
maintained in DMEM (G1BCO  BRL, Gaithersburg, MD) supplemented 
with  10%  FBS  (Hyclone,  Logan,  UT)  sodium pyruvate,  and pen/strep 
(Sigma Chem. Co., St. Louis, MO). All cells were grown in a humidified 
5 % CO2 atmosphere at 37°C in 100-mm tissue culture plates (Falcon, Bec- 
ton Dickinson Labware, Lincoln Park, N J). 
Subtractive Immunization 
C57 BL6 female mice, 6-8 wk old and 16-18 grams, were obtained from 
Charles River (Montreal, Quebec). The S.I. protocol was performed as fol- 
lows. On day 1, subconfluent M- HEp3 cell cultures were washed 3 x  with 
sterile PBS and harvested by the addition of 3 ml of nonenzymatic cell dis- 
sociation solution (Sigma Chem. Co., St. Louis, MO) for 1 min. Single cell 
suspensions  were  washed  and  resuspended  in  sterile  PBS  (4  x  106 
cells/ml). HEp3 M- cells (2  x  106) were inoculated i.p. into mice on day 
1. On days 2 and 3, mice were injected i.p. with 200 mg/kg cyclophospha- 
mide (Sigma Chem. Co., St. Louis, MO) in sterile PBS. On day 15 sera 
were collected and screened by the whole cell Enzyme Linked Immunoab- 
sorbnnt Assay (ELISA) (see below) for reactivity to M- HEp3 cells. On 
day 18 M + HEp3 cells were harvested as described above and 2  x  106 cells 
were inoculated i.p. into the mice. On day 39, mice received an i.p. boost 
of 3  x  106 M + HEp3 cells. On day 42, sera were collected and screened 
for differential reactivity toward both the M + HEp3 and M- HEp3 cells in 
the whole cell ELISA. On day 43, the mouse with the greatest M+/M  - ra- 
1.  Abbreviations  used  in  this  paper:  CAM,  chorioallantoic membrane; 
ELISA, Enzyme Linked Irnmunoabsorbant Assay; HEp3, human epider- 
moid  carcinoma  cells;  M +,  metastatic  HEp3  cell  variant;  M-,  non- 
metastatic HEp3 cell variant; uPA, human urokinase type plasminogen acti- 
vator; S.I., subtractive immunization. 
tio was sacrificed for the production of hybridomas (10). Variations of the 
S.I. protocol were carried out in which cyclophosphamide  was given either 
at 120 and 96 h before the M- HEp3 cells or 1 and 24 h after the M- HEp3 
cells. A control protocol was performed that was exactly the same as the 
S.I. protocol except that no cyclophosphamide was given. 
Production of  Hybridomas 
Hybridomas were produced by standard methods (6). Briefly,  the spleens 
and accessory lymph nodes were removed, washed, and fused (4:1 spleen 
to myeloma) with the mouse myeloma cell line NSO (10).  The cells were 
plated (2.5  ×  104 cells/0.1  ml HAT medium/well) in 96 well tissue culture 
plates  (Falcon,  Becton Dickinson Labware).  Culture  supernatants were 
screened by the whole cell ELISA and hybridomas from each of the immu- 
nization protocols were cloned by soft agar and limiting dilution. Each posi- 
tive hybridoma was cloned twice. 
Whole Cell ELISA 
Subconfluent monolayer cultures of HEp3 cells as well as various other cell 
types were washed 3 x  in sterile PBS, removed with nonenzymatic cell dis- 
sociation solution, washed in sterile PBS, and resuspended in DMEM con- 
taining 10% FBS. Cells were added (2 x  104/0.1 ml/weli) to 96 well tissue 
culture plates and allowed to attach for 36 h in a humidified atmosphere of 
5% COz at 37°C. Cells were washed 3x  with PBS and fixed with 0.25% 
glutaraldehyde in PBS (0.1 ml/well) for 10 min. The plates were washed 3x 
with PBS, blocked with 1.0 M glycine, pH 8.1 (0.1 rni/well), for 2 h at room 
temperature, washed 3x with PBS, and used directly or stored in 0.1% so- 
dium azide in PBS at 4°C. Stored plates were washed 3x  with PBS (no 
azide) just before assay. 
The washed, cell-coated wells were blocked with DMEM containing 
10%  FBS  (0.2  ml/well)  overnight at  4°C.  Hybridoma  supernatants or 
purified mAbs were added to the wells and incubated for 2 h at room tem- 
perature. ELISA plates were washed 3x with 0.5% BSA, 0.05%  Tween-20 
in PBS. Alkaline phosphatase-labeled goat anti-mouse IgG and IgM (heavy 
and light chain specific) (Cappel, Malvern, PA) was added (1:1,000 in 1% 
BSA/PBS) and incubated for 2  h  at room temperature. The plates were 
washed and the substrate, p-nitrophenyl phosphate disodium (2 mg/ml in 
25 mM NaHCO3, and 1 mM MgC12 pH 9.8),  was added (50 #l/well) and 
incubated for 30 min at 37°C. The ELISA plates were read at 405 um on 
a Titer Trek Multiscan plate reader. Nonspecific binding was determined 
using preimmnne sera or normal mouse IgG (Cappel) and subtracted from 
the  experimental  samples.  ELISA  ratios  were  calculated  as  follows: 
(OD405 M + HEp3/OD405 M- HEp3). 
Monoclonal Antibody Purification 
Hybridoma conditioned media was centrifuged at 3,000 g for 30 min, con- 
centrated  10×  with  an  Amicon  Stirred  Cell  Concentrator  (Amicon, 
Beverly,  MA) and  filtered through a  0.22-#m  filter (Acrodisc, Gelman 
Sciences, Ann Arbor, MI). The concentrated conditioned medium was ap- 
plied to a protein G Superose column (Pharmacia LKB Biotechnology, Pis- 
cataway,  NJ) connected to a FPLC (Pharmacia LKB Biotechnology) and 
mAbs were eluted with 0.1 M glycine pH 3.0. Purified mAbs were immedi- 
ately neutralized with 1.0 M Tris, pH 9.0, dialyzed against PBS, and stored 
at  -20°C. 
Chick Embryo Metastasis Assay 
Fertilized COFAL- negative eggs were obtained from SPAFAS (Norwich, 
CT) and incubated in 37°C with 60% humidity for 10 d. The chick embryo 
metastasis assay is a modification of procedures previously described (12, 
34). Briefly,  a small hole is made through the shell at the end of the egg 
directly over the air sac with the use of  a small crafts drill (Dremel, Division 
of Emerson Electric Co., Racine, WI). A second hole is drilled on the broad 
side of the egg directly above embryonic blood vessels, which are located 
previously by candling the egg. Negative pressure is applied to the original 
hole, resulting in the chorioallantoic membrane (CAM) pulling away from 
the shell membrane and creating a false air sac over the CAM. A 0.5 cm 
x  0.5 cm square window is cut through the shell with the use of a small 
model grinding wheel (Dremel, Division of Emerson Electric Co.) which 
allows direct access to the underlying CAM. M + HEp3 cells (2  x  105/20 
~1 serum-free DMEM) are placed on top of  the CAM through the small win- 
dow. The window is sealed with sterile tape and the embryos are placed back 
in the incubator. 24 h later a second small window is carefully cut in the 
side of the egg shell directly over prominent blood vessels and the outer egg 
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drop of paraffin oil is added to the exposed membrane to allow the mem- 
brane to become transparent and blood vessels to be easily visualized. 
Purified mAbs are inoculated (200 #g/0.1  ml PBS) directly into the blood 
vessels with a 30 gauge needle. The windows are sealed with sterile tape 
and the embryos are allowed to incubate until day 17. On day 17 the embryos 
are sacrificed and the primary HEp3 CAM tumors are removed, trimmed, 
and weighed. The embryonic lungs are removed, finely minced with a pair 
of small sterile dissection scissors, transferred to the CAMs of a second set 
of 10-d old embryos prepared as described above, and incubated until day 
17. This embryonic lung transfer allows for the expansion of micrometasta- 
sis that might be present in the original chick embryo lungs. The second 
set of embryos are sacrificed at day 17 and the resulting lung tumors are 
removed from the CAM. The lung tumors are finely minced and morpho- 
logically assayed for the presence of HEp3 cells. The HEp3 cells, easily 
identified due to their large size and morphology compared to the chick lung 
cells,  are  counted  using  a  phase  contrast  microscope.  Five  randomly 
selected fields are counted and the number of HEp3 cells per field is calcu- 
lated. The lung metastases are also quantitated by a human plasminogen 
activator assay (uPA) (see below). 
Plasminogen Activator Assay 
Lung tumor minces were placed on ice, homogenized with a tissue grinder 
(Biospec Products, Bontlesville, OK) in 0.9 ml of extraction buffer (25 mM 
Tris, 0.5 % TX-100, pH 8.1) and insoluble material was removed by centrifu- 
gation at 10,000 g for 10 min. The concentrations of protein in the lung tu- 
mor extracts were determined by the BCA method (Pierce). Lung tumor ex- 
tracts at a protein concentration of 0.1 mg/ml were assayed for human uPA 
activity.  The uPA assays (9) were performed in 96 well fiat bottom ELISA 
plates (NUNC, Roskilde, Denmark). Lung tumor extracts (10/~1 of the 0.1 
mg/ml) were incubated with purified human plasminogen (3/~g/well) for 
2 h at 37°C. The $2251  chromogenic substrate (Kabi Vitrum, Stockholm, 
Sweden) was added (15  tzg/3-/~l extraction buffer) to each well and the 
ELISA plates were incubated at 37*C for 0,  15, 30, 60, and 90 min. The 
absorbance at 405 nm was mad at each time point with a multiscan plate 
reader. The human uPA activity was calculated by comparison of  the sample 
values with a standard curve derived from human urokinase standards (Leo 
Pharmaceutical Products, Denmark). uPA activity was calculated as milli 
units of human uPA activity per mg of lung protein. 
Immunofluorescence 
HEp3 M + cells (1.5 ×  l0  s) were grown for 24 h on sterile glass coverslips 
(Rochester Scientific, Rochester, NY)  in an atmosphere of 5 %  CO2  at 
37"C. The media was removed and the cells were washed 2×  with PBS. 
The cells were fixed with 3 % paraformaldehyde for 5 rain, washed 3 ×  with 
serum free DMEM and blocked with 1.0 M glycine for 10 rain to prevent 
nonspecific binding. The cells were washed 3 ×  with serum free DMEM, 
blocked with  1%  gelatin for  10  rain,  and washed 2×  with serum free 
DMEM. Primary rnAbs were added at a concentration of 20 tzg/ml and in- 
cubated for 30-45 rain at room temperature. Cells were washed 5 ×  with 
serum free DMEM for 5 rain each. FITC-conjugated goat anti-mouse IgG 
(TACK), Burlingame, CA) was added at a 1:20 dilution in DMEM for 30-45 
min at room temperature. Cells were washed 5 ×  with DMEM and 3 × with 
PBS  for 5  min each.  One drop of mounting  medium containing 50% 
glycerol, 50% PBS was added to the coverslip  and the coverslip was inverted 
on a glass slide. The slides were analyzed for FITC immunofluorescence 
by confocal microscopy. 
Western Blot Analysis 
HEp3 cells were grown to confluence in 100-mm tissue culture plates and 
washed 3 x  with PBS. Whole cell lysates were prepared by the addition of 
1 ml oflysis buffer (0.1 M Tris pH 8.0, and 1.0% TX-100 supplemented with 
a protease inhibitor mixture including 5 mM EDTA, 20 #g/mi Leupeptin, 
30 #g/ml TPCK, 20 #g/ml SBTI and 20 U/ml Aprotinin). The lysates were 
incubated with agitation for 10 min at 4"C and centrifuged at 3,000 g for 
10 rain to remove detergent insoluble materials. M + HEp3 lysates (20 #g 
protein) were electrophoresed through either a  10 or 7.5% SDS-PAGE gel 
under nonreducing conditions (20). The proteins were transferred by elec- 
troblotting onto nitrocellulose membranes. The blots were blocked with 5 % 
non-fat milk, incubated with either mAb DM12-4,  1AS, or normal mouse 
IgG at 4"C overnight, and washed 4x with 0.1% Tween-20 in PBS for 15 
rain. Peroxidase-labeled  goat anti-mouse IgG was added as secondary anti- 
body. The immunoblots were washed as before and developed with the che- 
miluminescence  ECL  system  (Amersham  International,  UK)  as  per 
manufacturer's protocol. 
Statistical Analysis 
Statistical analysis was carried out by applying ANOVA and Newman-Keuls 
multiple range tests (50). 
Results 
Immune Suppression of  M- HEp3 Cells by 
Cyclophosphamide Treatment 
A  number of cyclophosphamide-treatment protocols  were 
employed to suppress the immune system of mice to highly 
reactive  immunodeterminants  present  on M-  HEp3  cells, 
inoculated as the initial immunogen. In two protocols, mice 
were inoculated with M- HEp3 cells followed a short time 
later with two injections of cyclophosphamide.  In another 
immunization protocol the mice  were  pretreated  with cy- 
clophosphamide  120 and 96 h before the inoculation with 
M-  HEp3  cells.  The control protocol employed the same 
sequence of inoculations except that no cyclophosphamide 
was used.  In all of the protocols,  sera were collected  15 d 
Table L  Suppression of Immune Response to 
M- HEp3 Cells 
Mouse  Cyclophosphamide  Dilution of  ELISA OD U 
number  treatment  day 15 Sera  (A40~) 
D-1  None  1:50  0.276 (+  0.086) 
1:100  0.161  (+  0.033) 
1:500  0.064 (+  0.011) 
D-2  None  1:50  0.211  (+  0.001) 
1:100  0.140 (+  0.007) 
1:500  0.070 (+  0.003) 
A-1  -120  and  1:50  0.114  (+  0.001) 
-96  h  1:100  0.063  (+  0.006) 
1:500  0.033  (+  0.003) 
A-2  -120  and  1:50  0.083  (+  0.004) 
-96  h  1:100  0.051  (+  0.007) 
1:500  0.033  (+  0.004) 
B-1  1 and  1:50  0.094  (+  0.023) 
24 h  1:100  0.059  (+  0.013) 
1:500  0.021  (+  0.005) 
B-2  1 and  1:50  0.096 (+  0.020) 
24 h  1:100  0.038  (+  0.017) 
1:500  0.015  (+  0.015) 
C-I  24 and  1:50  0.000 
48 h  1:100  0.000 
1:500  0.000 
C-2  24 and  1:50  0.010 (+  0.004) 
48 h  1:100  0.000 
1:500  0.002  (+  0.001) 
Mice  were  inoculated  i.p.  with  2  x  106  M-  HEp3  cells  (prepared  as 
described in Materials and Methods) and treated with cyclophosphamide  (200 
mg/kg) as indicated. The mice from group A received cyclophosphamide 120 
and 96 h before M- HEp3 inoculation.  Sera from each mouse was collected 
on day 15 and diluted  1:50,  1:100,  and 1:500 with PBS.  The sera dilutions 
were added (100 #1) to duplicate  wells of ELISA plates containing  2  x  104 
M- HEp3 cells/well. Whole cell ELISAs were carried out as described in 
Materials  and Methods. ELISA values (OD at 405 nm) were determined from 
duplicate  experiments and  corrected by  subtracting  OD  U  resulting  from 
binding of preimmune sera.  The SD is given in (+). 
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M- HEp3- Suppressed Mice after Inoculation of 
M  + HEp3 Cells 
Mouse  Cyclophosphamide  Serum ELISA ratio 
number  treatment  (M  ÷ HEp3/M- HEp3) 
D-1  None  1:22  (+  0.22) 
D-2  None  1.27  (+  0.03) 
A-1  -120 and  -96 h  1.26 (+ 0.10) 
A-2  -120 and  -96 h  1.35 (+ 0.14) 
B-1  1 and 24 h  1.65 (+ 0.06) 
B-2  1 and 24 h  1.47 (+ 0.07) 
C-1  24 and 48 h  1.88 (-I- 0.07) 
C-2  24 and 48 h  1.86 (+ 0.09) 
The groups of M- HEp3-inoculated mice that had been treatexl or pretreated 
with cyclophosphamide were inoculated i.p.  with 2  x  106 M  + HEp3 cells on 
day  18 and again with 3  x  106 M  + HEp3 cells on day 39. On day 42,  serum 
from each mouse was collected, diluted 1:100 with PBS, and tested in duplicate 
matched whole cell ELISA plates coated with either 2  x  104 M  + HEp3 cells 
or 2  x  104 M- HEp3 cells.  The ratio of the OD~o5 values for M  + HEp3/M- 
HEp3 was calculated.  The SD values are given in parentheses. 
after  the  initial  inoculation  with  M-  HEp3  cells  and 
screened in whole cell ELISAs for reactivity to M- HEp3 
cells. 
As indicated in Table I, control sera from mouse group D 
(no cyclophosphamide treatment) had a  positive reactivity 
toward the M- HEp3 ceils at all dilutions tested. Sera col- 
lected from mice that were pretreated with cyclophospha- 
mide (group A) still showed reactivity toward the M- HEp3 
ceils but their titer was reduced 2-3-fold as compared to the 
control  mice.  Sera  collected  from mice  treated  with  cy- 
clophosphamide  1  and  24  h  after  the  initial  inoculation 
(group B) exhibited low reactivity towards M- HEp-3 cells 
while  the  sera  from mice  treated  24  and  48 h  with  cy- 
clophosphamide (group C) showed negligible or no detect- 
able reactivity towards the M- HEp3 cells. The 24 and 48 h 
cyclophosphamide treatment protocol thus results in a pro- 
nounced reduction of the immune response to the M- HEp3 
cells indicating a suppression to the antigenic determinants 
on  the  M-  HEp3  cells.  A  series  of similar  experiments 
using  differently  timed  injections  (data  not  shown)  con- 
firmed that the most efficient immunosuppression resulted 
from cyclophosphamide treatment that was performed 24 h 
and 48 h  after the initial inoculation of antigen. 
Enhancement of  Immune Response to M ÷  HEp3 Cells 
Immunization with  M + HEp3  ceils  was performed on all 
mice on day 18,  15 d after the last cyclophosphamide treat- 
ment, and again on day 39.  On day 42,  sera was collected 
and screened for reactivity to both M ÷ and M- HEp3 cells 
in  duplicate  matched  whole  cell  ELISAs.  The  M+/M  - 
ELISA ratios were calculated for all of the mice (Table 1I). 
The results indicated that mouse C-l, which had been treated 
with cyclophosphamide 24 and 48 h after M- HEp3 inocu- 
lation, had the highest M÷/M  - ELISA ratio of 1.9 while the 
sera from the control mice (no cyclophosphamide treatment) 
had a M+/M  -  ELISA ratio of 1.2-1.3.  The mice pretreated 
with  cyclophosphamide  yielded  M÷/M  -  ratios  indistin- 
guishable from that of the control,  while the mice treated 
with cyclophosphamide at 1 and 24 h after M- HEp3 inocu- 
lation were intermediate between the control and the 24 and 
Table III. Summary of Total HEp3-Reactive Hybridomas 
Whole cell ELISA ratio 
Mouse  Cyclophosphamide  M  + HEp3/M- HEp3  % of Total 
number  treatment  (OD4odOD,~)  hybridomas* 
D-1  None  2.0 or >2.0  3% 
0.5-1.9  94% 
<0.5  3% 
B-1  1 and  2.0 or >2.0  18% 
24 h  0.5-1.9  82% 
<0.5  0% 
C-1  24 and  2.0 or >2.0  26% 
48 h  0.5-1.9  74% 
<0.5  0% 
Conditioned media (100 #1) from hybridoma clones prepared  from the three 
indicated mice were screened in the whole cell ELISA for reactivity with both 
M  + HEp3 and M- HEp3 cells.  Only hybridoma clones having ELISA OD~ 
U of greater than 0.050  and at least 3x  the background  (100 #1 of medium 
alone)  were  included  in the  calculation  of percentages.  ELISA  ratios  were 
calculated as follows: OD U for binding of conditioned media to M  + HEp3 
cells  were divided  by the  OD  U  for binding  of conditioned  media  to  M- 
HEp3 cells.  Data were derived  from triplicate experiments. 
* n value for mouse D-1  =  350; B-1  =  211; and C-1  =  50. 
48 h cyclophosphamide-treated animals. The sera data indi- 
cates  that  cyclophosphamide  suppressed  the  immune  re- 
sponse to M-  HEp3  cells  (Table I) and permitted an en- 
hanced differential response to M + HEp3 cells (Table II). 
Generation of mAbs from Control and 
Experimental Mice 
Hybridomas were generated from mice C-l, B-l, and control 
D-1.  Conditioned media from all of the hybridoma clones 
(611 total clones) were screened in comparative whole cell 
ELISAs for binding to both the M ÷ and M- HEp3 cells.  A 
summary of these results are shown in Table 11I. The C-1 
mouse that was treated with cyclophosphamide at 24 and 
48 h  after  the  initial  inoculation  and  had  exhibited  the 
greatest immune suppression towards M- HEp3 cells (Ta- 
ble I), yielded 26% hybridomas with M÷/M  - ELISA ratios 
of 2.0 or greater. The B-1 mouse, that was treated with cy- 
clophosphamide at 1 and 24 h after the initial inoculation of 
HEp3  M-  cells,  yielded  hybridomas  of which  18%  had 
M+/M  -  ELISA ratios of 2.0 or greater.  The great majority 
(94%) of the hybridomas produced from the control mouse 
D-1  had  M+/M  -  ELISA  ratios  between 0.5  and  1.9  with 
only 3 % of the hybridomas showing M+/M  -  ELISA ratios 
of 2.0 or greater. The S.I. protocol thus resulted in a substan- 
tial  increase  in  the  proportion  of hybridomas  that  were 
differentially reactive with molecules on the surface of M + 
HEp3 cells. 
From the C-1  mouse hybridomas a panel of mAbs were 
purified and evaluated by whole cell ELISA for their reactiv- 
ity to various human cell types. Table IV illustrates a repre- 
sentative sample of these purified mAbs including  a  mAb 
(FM40-4) that exhibited little or no enhanced reactivity to 
M ÷ HEp3 cells. The mAbs 1AS, DM12-4, and FM23-3 ex- 
hibited  M÷/M  -  ELISA ratios of 5.5,  2.4,  and 2.5,  respec- 
tively. All of these mAbs exhibited little or no reactivity to 
non-malignant human cells including normal fibroblasts and 
primary keratinocytes, mAb DM12-4 exhibited some reac- 
tivity to a series of highly malignant human tumor cells in- 
cluding  breast  adenocarcinoma,  cervical  carcinoma,  and 
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Human  Cell Types 
Human cell types tested in whole cell ELISA (OD,0s) 
mAb  M + HEp3  M- HEp3  MDA-MB231  MS751  HT-3  HT1080  HFF  KER 
tested 
FM40-4  0.288  0.233  0.037  0.000  0.001  ND  0.000  0.007 
-t-0.049  +0.113  -t-0.038  +0.008 
FM23-3  0.340  0.135  ND  0.030  0.031  0.126  ND  ND 
+0.048  +0.028  +0.007  +0.003  +0.007 
DM 12-4  0.424  0.178  0.105  0.071  0.084  0.041  0.012  0.003 
+0.008  +0.001  +0.007  +0.013  +0.004  +0.025  +0.016  +0.004 
1A5  0.312  0.057  0.002  0.000  0.014  ND  0.000  ND 
+0.003  +0.003  +0.002  +0.003 
Purified mAbs were screened in a comparative whole cell  ELISA to determine their reactivity to various human cell types (2  ×  104 cells/well). ELISA values 
are expressed as OD,~ U minus the background values (normal mouse IgG). Assays were performed two to three times with the average of duplicate or triplicate 
wells determined +SD. M  + HEp3, metastatic Human Epidermoid Carcinoma; M- HEp3, nonmetastatic Human Epidermoid Carcinoma; MDA-MB 231, Human 
Adenocarcinoma of the breast; MS751, Human Cervix Epidermoid Carcinoma; HT-3, Human Cervical Carcinoma; HTI080, Human Fibrosareoma; HFF, Human 
Foreskin Fibroblasts; KER, Human Primary Keratinocytes; ND indicates not determined. 
fibrosarcoma cells.  The  reactivity of this  mAb  to  these 
malignant cells, however, was 4-10-fold lower than its im- 
munoreactivity  to  M ÷  HEp3  cells,  mAb  1A5  also  was 
highly reactive to M ÷ HEp3 cells but showed little or no re- 
activity to the other malignant human tumor cells including 
the tumorigenic but non-metastatic M- HEp3 cells. 
Anti-Metastatic Effect of mAbs 
To ascertain if the cellular determinants that are recognized 
by  the  various  mAbs  are  involved  functionally  in  the 
metastatic cascade, the mAbs were screened in the chick em- 
bryo metastasis assay model system (12, 34). Purified mAbs 
were inoculated i.v. into ll-d old chick embryos previously 
implanted  on day  10 with  M + HEp3  cells  (see Materials 
and Methods). The mAbs were analyzed for their effect on 
spontaneous metastasis (HEp3 cells appearing in the lung) 
as  well as tumorigenicity (HEp3 primary tumor growth). 
The results  shown in Table V  indicate that inoculation of 
mAb  DM12-4  resulted in  a  dramatic  reduction in  HEp3 
metastasis, as indicated by an 84 % inhibition of the number 
of HEp3 cells found in the chick lungs and an 86 % inhibition 
of the amount of human uPA activity measured in the lung 
tumors as compared to controls. A strong linear correlation 
(r =  0.870) exists between the number of HEp3 cells found 
in the lung and the amount of human uPA activity measured 
in the lung tumors (12,  31, 34, 35, 46). The mAb DM12-4 
exhibited no significant effect  on tumorigenicity as compared 
to the control thus demonstrating its specific effect on tumor 
metastasis. The mAb 1AS also substantially inhibited HEp3 
metastasis  to  the  lung.  Inoculation  of purified  1AS  IgG 
caused a 93 % inhibition of the number of HEp3 cells found 
in the chick lungs and a 90% inhibition of the appearance 
of human uPA activity in the lung tumors but had no effect 
on primary tumor growth. The mAbs FM23-3 and FM40-4 
which are isotype matched IgGl subtypes that also bind to 
the surface of M + HEp3 cells (Table IV), demonstrated no 
significant  effect on  lung  metastasis  and  primary  tumor 
growth (Table V). Since both mAbs, FM23-3 and FM40-4, 
did not inhibit metastasis but bound strongly to M ÷ HEp3 
cells, the pronounced inhibition of metastasis observed with 
DMI2-4 and IA5 mAbs was not due simply to nonspecific 
or steric interactions caused by mAbs binding to the HEp3 
cell surface. 
The inhibition of metastasis by rnAbs DM12-4 and 1A5 
also does not appear to be due to a cytotoxic effect of the 
mAbs on the HEp3 cells because no significant change in 
primary tumor weights was  observed (Table V).  Further- 
more mAbs DM12-4 and 1A5 were examined for any effect 
on HEp3 cell growth in vitro. Fig.  1, A and B shows that 
HEp3 cell growth was not affected by incubation with mAb 
DM12-4 or 1A5 in comparison to either HEp3 cell growth 
in the presence of control normal mouse IgG or no antibody 
additions. 
Properties of the Antigens Recognized by the 
Anti-Metastatic Antibodies 
The anti-metastatic mAbs DM12-4 and IA5 were originally 
detected by whole cell ELISA indicating that they were reac- 
tive  to  M ÷  HEp3  cell  surface  immunodeterminants.  To 
confirm the  localization of the  molecules  recognized by 
mAbs DM12-4 and 1A5, M ÷ HEp3 cells were analyzed by 
indirect immunofluorescence and confocal microscopy. Fig. 
2 a  illustrates a transmitted light photo micrograph of M ÷ 
HEp3 cells. Fig. 2 b shows a immunofluorescent micrograph 
illustrating  the  reactivity of mAb  DM12-4  to  M + HEp3 
cells in the same field. The staining pattern indicates that 
mAb DM12-4 recognizes epitopes localized to the lateral 
and peripheral edges of the surface of M ÷ HEp3 cells. Fig. 
2 c and d is transmitted light and immunofluorescent micro- 
graphs of M ÷ HEp3 ceils stained with normal mouse IgG. 
No distinct staining pattern is observed indicating that the 
distribution and localization of the molecules recognized by 
mAb DM12-4 are specific and not due to nonspecific binding 
of IgG. The mAb 1AS also exhibited distinct localization to 
the cell surface of M + HEp3  (data not shown) consistent 
with its immunoreactivity in whole cell ELISA (Table IV). 
To determine the nature and specificity of the antigens 
recognized by the anti-metastatic mAbs DM12-4 and 1A5, 
M ÷ HEp3 whole cell lysates were electrophoresed in non- 
reducing SDS-PAGE gels and probed by Western blotting 
(Fig.  3).  In Fig.  3 A,  M + HEp3 whole cell lysates were 
probed with either mAb DM12-4 (lane/) or normal mouse 
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Primary  HEp3 cells  in  Human uPA in 
mAb  tumor  % of  lung tumors  % of  lung tumors  % of 
inoculation  (mg)  control  (Cells/Field)  control  (m U/mg)  control 
None  322.6  100  13.5  100  4,344  100 
+32.9  +1.1  +816 
FM40-4  323.5  100  12.6  93  3,931  91 
+62.9  +3.1  +683 
FM23-3  347.1  108  11.9  88  3,941  91 
+32.1  +1.7  +921 
DM12-4  307.8  95  2.2  16  599  14 
-I-22.8  -1-0.4  -t-144 
IA5  309.1  96  1.0  7  440  10 
+ 10.4  +0.3  +86 
Purified mAbs were screened in the chick embryo metastasis assay as described in Methods. Briefly, 2  x  105 highly metastatic M  + HEp3 cells were implanted 
directly onto the chorioallantoic membrane (CAM) of 10-d old embryos to initiate primary tumor growth.  24 h later,  embryos was inoculated i.v.  with 200 #g 
of purified mAb in 100 td of sterile PBS. 6 d later the embryos were sacrificed and the primary HEp3 tumors on the CAM were removed and weighed. Embryonic 
lungs were dissected out and transferred  onto the CAMs of a second set of 10-d old embryos to allow for expansion of any HEp3 micrometastases present in 
the lung. The second set of embryos was incubated for 6 d. Metastasis was quantitated morphologically by counting the number of HEp3 cells in the resulting 
lung tumor, as well as enzymatically for the presence of human urokinase type plasminogen activator (uPA) in the lung tumors.  Data were derived  from three 
to four independent experiments each containing 4-6 embryos per antibody inoculation. Values are expressed as means of each experiment,  +  standard error along 
with the  % of control relative to no antibody inoculation. 
IgG (lane 2). The mAb DM12-4 recognizes a major protein 
band migrating at ~55 kD.  Minor immunoreactive protein 
bands could also be detected migrating at ,,o70, 100,  and 
>110 kD.  Fig. 3 B illustrates Western blot analysis of M ÷ 
HEp3 lysates probed with mAb 1A5 IgG (lane/) or normal 
mouse IgG (lane 2). The mAb 1A5 IgG recognized a single 
protein band migrating at *29 kD.  No protein bands were 
detected in M ÷ HEp3 cell lysates when probed with normal 
mouse IgG indicating the specificity of the major 55 and 29 
kD  proteins recognized by mAbs  DM12-4  and  1A5  IgG, 
respectively. 
Discussion 
The identification of specific molecules involved function- 
ally in the multistep process of tumor metastasis is made 
difficult due to the complexity of the various in vivo steps 
in the metastatic cascade. Metastatic processes such as tu- 
mor cell growth,  migration,  invasion, and adhesion have 
been studied individually in various cell culture model sys- 
tems (1, 3, 4, 28). A significant number of molecules includ- 
ing growth factors, adhesion glycoproteins and proteolytic 
enzymes have been correlatively, and in some cases func- 
tionally linked to phenotypic behavior of the cells in the cul- 
ture model systems (5,  13, 30, 41). Very few of these mole- 
cules, however,  have been tested rigorously in the overall 
process of metastasis and shown to be functionally involved 
in vivo. In the present study a subtractive immunization ap- 
proach has been used to immunologically identify specific 
molecules, present on the surface of highly metastatic hu- 
man tumor cells, that function mechanistically in the overall 
process of metastasis.  This subtractive approach,  in con- 
junction with sequential screening of antibody binding to 
metastatic cells and antibody-mediated inhibition of metas- 
tasis, allows the immunological approach itself to select out 
relevant antigen molecules. The selection is carried out with- 
out any experimental bias towards a favored class of mole- 
cules such as enzymes, growth factors, or adhesion mole- 
cules and instead the relevancy of the antigen is dictated by 
the results of the screening process. The selective pressure 
of screening for a monoclonal antibody that specifically in- 
hibits the final outcome of metastasis, i.e., appearance of tu- 
mor cells in a secondary organ, provides strong evidence that 
the antigen recognized by the antibody is involved in the 
mechanism of metastasis. 
The subtractive approach taken in the present study was 
used in conjunction with a human tumor cell line HEp3, that 
had been shown previously to be highly tumorigenic and 
metastatic in both the chick embryo and nude mouse (12, 31, 
34, 35, 36, 46). Specific molecules on the surface of HEp3 
cells might indeed contribute to HEp3's metastatic pheno- 
type, and antibodies to such molecules would be extremely 
useful. Immunizing mice directly with HEp3 cells, however, 
would  likely  yield  an  immune  response  mainly  to  im- 
munodominant antigens present on the surface of many hu- 
man cells as suggested by studies employing direct immuni- 
zation of target cells (19, 27, 49).  It is probable that many 
of the immunodominant molecules are not directly involved 
in the metastatic process.  Their immunodominance, how- 
ever, make it difficult to isolate antibodies to rare and possi- 
bly low immunogenic molecules that might have a significant 
role in metastasis. The subtractive immunization protocol 
whereby the non-metastatic variant of HEp3 cells, M- HEp3, 
is inoculated into mice and the resulting immunoreaction is 
suppressed by cyclophosphamide, allows for a  subsequent 
shift in the immunological response upon challenging the 
mice with the highly metastatic variant, M ÷ HEp3. 
A  clear  suppression  of immune response to intact M- 
HEp3  cells  occurred  in  mice  inoculated with  M-  HEp3 
cells when cyclophosphamide was injected 24 and 48 h after 
the initial inoculation of M- HEp3  (Table  I).  Upon chal- 
lenge of the suppressed mice with M + HEp3, a shift in the 
immune response was apparent as a greater immune reactiv- 
ity to M + HEp3 over M- HEp3 became apparent in the an- 
tibody titers of  the serum from the cyclophosphamide  treated 
animals (Table II). Although only a modest change in the 
M+/M  -  immunoreactivity ratio  over  the  control  animals 
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Figure 1. Effect of mAbs DMI2-4 and IA5 on M  + HEp3 growth in 
vitro. M  ÷ HEp3 cells (2  x  105) were added to 60-mm tissue cul- 
ture plates in 2 ml of DMEM containing 10% FBS and incubated 
at 37°C for 1 h. The incubation allowed 80-90% of the cells to be- 
come adherent. The plates were washed 3 x  with PBS and 2 ml of 
DMEM containing 10% FBS supplemented with either 50/zg/ml 
normal mouse IgG, mAb DMI2-4 (A), or mAb IA5 (B) was added 
to the plates. Cultures were incubated at 37°C in an atmosphere of 
5% CO2 for 24, 48, and 72 h. At each time point the cells were 
removed from the plates with nonenzymatic cell dissociation solu- 
tion, counted in a hemocytometer and calculated for the number 
of cells per plate. The data in each panel were derived from two 
separate experiments. 
(1.9 vs 1.3) was apparent, it is important to note that serum 
immunoreactivity represents the total antibody population of 
the immunized animal.  Antibodies reacting uniquely or at 
enhanced levels to M + HEp3 would be masked in the over- 
all population of circulating antibodies since even in the S.I. 
protocol most antibodies would still be reactive to antigens 
common to both M + HEp3 and M- HEp3 cells. In the im- 
munosuppressed  mice  the  enrichment  of antibodies  that 
recognize antigens expressed specifically,  or at elevated lev- 
els on M + HEp3 cells became more apparent when spleen 
Figure  2.  Indirect  immunofluorescence of M  ÷ HEp3  cells in- 
cubated with mAb DM12-4. M  ÷ HEp3 cells were grown on glass 
coverslips, fixed with 3 % paraformaldehyde and incubated with 20 
#g/ml of either mAb DM12-4 or normal mouse IgG as described 
in Materials and Methods. The cells were counter stained with 
FITC-conjugated  goat  anti-mouse  IgG  and  analyzed for  im- 
munofluorescence by confocal microscopy. (a) Transmitted light 
micrograph of M  ÷ HEp3 incubated with mAb DM12-4. (b) Im- 
munofluorescent micrograph of the same field of cells in a.  (c) 
Transmitted light micrograph of M  ÷ HEp3 cells incubated with 
normal mouse IgG. (d) Immunofluorescent  micrograph of  the same 
field of cells in c. The 10/~m bar is indicated in the lower left of 
each panel. 
cell hybridomas are analyzed individually (Table  HI). The 
results  indicate that the cyclophosphamide-treated animals 
yield a  greater proportion of B cells producing antibodies 
that react differentially with M + HEp3 over M- HEp3 cells. 
The subtractive approach was not absolute or complete since 
antibodies reactive solely to M ÷ HEp3 cells were never ob- 
served. Nevertheless a clear enhancement of the immune re- 
sponse to antigens on the M ÷ HEp3 cells was obtained (Ta- 
bles III and IV). The tolerizing effects of cyclophosphamide 
are not permanent and mice begin to recover from the in- 
duced  tolerance  with  time  if the  initial  antigen  and  cy- 
clophosphamide  inoculation  schedule  is  not  cyclically 
repeated (24, 27). It may be possible to complete or prolong 
the tolerance and enhance the possibility of obtaining anti- 
bodies uniquely reactive to the challenged immunogen (M  ÷ 
HEp3) by repeated inoculation of M-HEp3 followed by 24 
and 48 h cyclophosphamide treatments before the M+HEp3 
challenge.  However,  multiple  cyclophosphamide inocula- 
tions were often lethal to the mice and complete tolerization 
to M-HEp3 was never achieved. 
The distinct success of the subtractive protocol used in the 
present  study  was  most  apparent  in  the  procurement  of 
specific antibodies that are anti-functional in their effect on 
M + HEp3's phenotype (Table  V).  Both DM12-4 and  1A5 
mAbs had a pronounced inhibitory effect on the spread of 
HEp3 cells to the lungs. The inhibition was not due to a cyto- 
toxic effect since the antibodies did not significantly reduce 
the size of the expanding primary tumors (Table V) nor did 
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immunodeterminants present in M  + 
HEp3 cell lysates and recognized by 
mAbs DM12-4 and IA5. Cell lysates 
of M  + HEp3 ceils  (20 /xg protein) 
were electrophoresed in either 7.5 % 
(A) or 10% (B) polyacrylamide SDS 
gels under non-reducing conditions. 
The gels were blotted onto nitrocel- 
lulose,  incubated with  either  mAb 
DM12-4 (A) or IA5 (B) and visual- 
ized  with  a  peroxidase-conjugated 
goat anti-mouse IgG by chemilumi- 
nescence.  Lane  1  in  each  panel 
represents the reactivity of the mAb 
and lane 2 that of  normal mouse IgG. 
Molecular weight standards electro- 
phoresed in parallel lanes of the gels 
are indicated on the left in kilodal- 
tons (kD). 
they affect growth of the HEp3 cells in culture (Fig.  1). A 
second possibility  to  explain the  inhibition  of metastasis 
might be a non-specific, steric inhibition by IgG molecules 
binding to the surface of HEp3 cells thereby interfering with 
the  dissemination  of  HEp3  cells  or  their  arrest  in  the 
microvasculature of the secondary organ.  This possibility 
does not seem likely since two other mAbs,  FM23-3 and 
FM40-4,  that also  bind to  M ÷ HEp3,  and  in the case of 
FM23-3 bind at elevated levels to M ÷ HEp3 cells did not 
inhibit  metastasis  (Table  V).  Therefore  it  appears  that 
specific antigen recognition by mAbs DM12-4 and  1A5 is 
responsible for the inability of  the HEp3 cells to successfully 
complete the metastatic cascade in the antibody-inoculated 
embryos. The antigens recognized by the two mAbs are dis- 
tinct, cell surface molecules that by Western blotting yield 
apparent molecular weights of 55 and 29 kD. Investigations 
are under way to characterize and identify these two antigens 
and to determine how and when these molecules function in 
metastasis. 
The subtractive immunization approach has yielded addi- 
tional  monoclonal antibodies  that  in  preliminary  experi- 
ments also appear to be anti-metastatic but studies on the na- 
ture  of the  antigens  recognized by  these  antibodies  are 
incomplete. Thus far none of the tested monoclonal antibod- 
ies that were derived from control animals (no cyclophos- 
phamide treatment) are anti-metastatic.  This is consistent 
with the observation that mAb FM40-4 which recognizes 
equally  M ÷ HEp3  and  M-  HEp3  (Table IV)  is  not  anti- 
metastatic (Table V). It would appear that the subtractive ap- 
proach enriches for antibodies that react with relevant func- 
tional antigens. It may be that functional antigens are rare or 
in low abundance on the cell surface relative to highly im- 
munodominant antigens that only a tolerization or suppres- 
sion event such as cyclophosphamide treatment allows for 
their immune recognition upon subsequent challenge with 
the  relevant target cell type.  Cyclophosphamide-mediated 
immune suppression has been used previously to obtain anti- 
bodies to rare or low abundance antigens on both normal and 
malignant cell types (18, 19, 26, 27, 48). The present study 
using both a  low and highly metastatic human tumor cell 
along  with  an empirically determined immunization pro- 
tocol has allowed for the first anti-metastatic antibodies to 
be procured by this subtractive approach. The protocol could 
engender a variety of experimental approaches designed to 
generate unique anti-functional antibodies in various biolog- 
ical systems where two closely related but phenotypically 
distinct cell or tissue types are available. 
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